Hemp Industry

German Cannabis Pioneer SynBiotic SE Files For Insolvency

SynBiotic SE, once one of the largest and most promising cannabis companies in Germany, has announced plans to file for insolvency and had its shares suspended on the Xetra and Frankfurt stock exchanges.

SynBiotic SE, once one of the largest and most promising cannabis companies in Germany, has announced plans to file for insolvency and had its shares suspended on the Xetra and Frankfurt stock exchanges.

It follows a year in which it had already lost six of its subsidiaries to insolvency, wind-down or disposal, seen its auditor refuse to issue an opinion, and in which its management had warned that the group’s continued existence depended on further capital that never materialised.

The group, which at its peak boasted 12 subsidiaries and a notional market capitalisation of around €85m at pre-crisis analyst valuations, blamed a persistently difficult cannabis market, a failure to secure financing in time, and a block on flexible capital measures after shareholders at its last annual meeting refused to approve the creation of new authorised capital.

One of Germany’s original players

Five years ago, when Business of Cannabis first covered the company, SynBiotic was in the process of completing what it described as the ‘most significant merger in the European cannabis sector’ to date, an €11.2m merger bringing Hanf Farm, Hempro International, Hemp Factory and MH Medical Hemp under one roof.

The seller, Daniel Kruse, was already a long-standing figure in the European hemp industry, a past president of the European Industrial Hemp Association (EIHA) and the owner of some of the sector’s longest-trading brands. The deal brought in his portfolio of brands, as well as Kruse himself, who came into the SynBiotic structure as part of the merger.

Its then-CEO and founder Lars Müller was weighing whether to keep buying companies or start building in-house ‘lifestyle brands’, noting that fundraising had become much easier in the aftermath of Germany’s announcement it intended to legalise cannabis. Full-year 2021 revenue guidance had just been raised to €15m, up from €5.4m in 2020.

The group’s cap table was unusual for a European cannabis play. SynBiotic had been backed since September 2021 by Christian Angermayer’s Apeiron Investment Group, the family office whose other health and biotech stakes include Compass Pathways and ATAI Life Sciences.

In November 2022, Canopy Growth founder Bruce Linton, the Canadian executive who had taken his company to a NYSE listing and secured Constellation Brands’ multi-billion-dollar entry into the cannabis sector, joined the SynBiotic register as an investor. By 2023, the group also carried the name of German media entrepreneur Frank Otto, of the Otto family, who invested €3m through a share package and joined the Verwaltungsrat alongside new chairman Oliver Conrad.

In the same August 2023 moves that brought in Otto, SynBiotic acquired a majority stake in CBD and lifestyle brand owner CannaCare Health, bringing in its Canobo CBD range and WellnetIQ network marketing arm. In the same week, Kruse took over from Müller as CEO, with Müller moving to managing director of the company.

A year later, SynBiotic took a 50.20% stake in Greensby UG, a European platform connecting patients, pharmacies and telemedicine providers in the cannabis market. CCO Emilio Ropero told Business of Cannabis the deal would allow the group to ‘optimally serve all market participants, from patients to consumers.’ Within weeks, the group had also moved its registered seat from Munich to Düsseldorf and lined up a 100% acquisition of Croatian CBD isolate manufacturer Ilesol Pharmaceuticals.

By early 2024, SynBiotic had positioned itself as the integrated European cannabis play its earliest investors had bet on, with brands, platforms and distribution spanning medical cannabis, industrial hemp and CBD.

With CanG set to transform the market in April 2024, SynBiotic looked poised to capitalise. On the surface, the group’s numbers followed. Consolidated sales jumped from €3.9m in 2023 to €14.3m in 2024, up 270.5%, and operating cash flow turned briefly positive at €0.7m.

What goes up…

However, those consolidated figures masked what was happening one level up at the SynBiotic SE holding company. While Germany’s cannabis market was being rapidly transformed, with patient numbers, prescriptions and import tonnage skyrocketing, the parent at the top of the structure was quietly haemorrhaging cash.

Instead of riding this wave of growth, SynBiotic found itself structurally exposed. Its medical cannabis spine ran through its WEECO Pharma import and wholesale platform, which was suddenly forced to compete at the lower end of the market, where prices were plummeting.

The CanG consumer growth went to the operators that actually owned the telemedicine clinics and the online pharmacies filling their prescriptions. SynBiotic sold wholesale into that chain but did not run any part of it, which left it absorbing the import price pressure without any of the consumer growth that was flowing above it.

The first whiff of trouble for investors came in October 2025, when SynBiotic nearly halved its outlook for full-year 2025, slashing its consolidated sales expectations from €30m to €17m and its profit outlook from €1.7m to a loss of €1.5m.

But the true extent of its financial struggles only became clear in December 2025 when its accounts for the previous year were filed, notably with its auditors refusing to sign off.

SynBiotic SE’s 2024 single-entity accounts, which cover the holding company on its own rather than the trading subsidiaries beneath it, show it closed 2024 with just €2,506.59 in cash at the bank. The parent recorded €7.18m in subsidiary impairments, a €9.12m loss after tax, an accumulated loss carryforward of €49.98m, and a €13.4m capital raise required just to keep it solvent through the year.

The group’s auditors, Forvis Mazars GmbH & Co. KG, refused to issue an opinion on the accounts, citing the company’s strained liquidity position and an inability to form a conclusion on the assumptions underlying management’s liquidity plan.

To bridge 2025, SynBiotic signed a contract with IRIS Capital Investment for €2.4m in interest-free convertible notes, alongside two further small capital increases of up to €187,500 and €200,000, both approved in the same week the auditors refused to give an opinion. That same week, its Austrian subsidiary Bushdoctor GmbH filed for insolvency.

From mid-2026, it began to dismantle its portfolio. First, Hempro International, one of the original 2021 Kruse acquisitions, filed for insolvency at the Amtsgericht Münster in June 2026. Then, in July, SOLIDMIND Group and Lean Labs Pharma followed, with the group citing CBD and hemp product revenue declines and regulatory uncertainty. By August, Hanf Farm had ceased operations entirely, and Hemp Factory had wound down its hemp food and feed arm.

At the same time, its house broker NuWays AG had placed its SynBiotic rating ‘Under Review’, having cut its target to €5.50 the previous December. Resources were now concentrated on WEECO Pharma, MH Medical Hemp, and Ilesol Pharmaceuticals, with WEECO alone estimated at around 90% of FY2026 sales.

The company cited a persistently difficult cannabis market, alongside shareholders voting to block the creation of new authorised capital during its last annual meeting, effectively closing the last financing route available to management.

SynBiotic expects a provisional insolvency administrator to be appointed and operations to continue initially. At the time of writing, no court decision had yet been published in Germany’s official insolvency register.

TopicsDaniel KruseForvis MazarsgermanyhempInsolvencyNuwaysSOLIDMINDSynbiotic

Ben Stevens

Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.

More from Ben

Spotted an error, or have a tip? Contact the newsroom.

Up next · Hemp Industry

Whole Hemp Plant Could Soon Be Recognised as Agricultural Crop in the EU, but States Will Keep Power to Criminalise

Ben Stevens · 29 October 2026

More